AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
177.96
-1.98 (-1.10%)
At close: 4:00PM EDT

179.29 +1.33 (0.75%)
Pre-Market: 8:02AM EDT

Stock chart is not supported by your current browser
Previous Close179.94
Open180.00
Bid177.05 x 800
Ask178.95 x 900
Day's Range176.99 - 180.26
52 Week Range153.56 - 201.23
Volume2,089,302
Avg. Volume4,739,814
Market Cap118.521B
Beta1.70
PE Ratio (TTM)66.16
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield5.28 (2.99%)
Ex-Dividend Date2018-05-16
1y Target EstN/A
Trade prices are not sourced from all markets
  • Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
    Market Realist1 hour ago

    Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?

    How Is Alnylam Pharmaceuticals Positioned in 2018? Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21. Overall, Alnylam Pharmaceuticals has fallen 24%.

  • Why this Peninsula startup is primed for an $80.5 million IPO
    American City Business Journals15 hours ago

    Why this Peninsula startup is primed for an $80.5 million IPO

    Kezar Life Sciences Inc., which would trade on the NASDAQ exchange as "KZR," is the fifth Bay Area life sciences company this year to file for an IPO, and it's indicative of the ability founders have to go public early on in the process of building a drug development company. Spun out of Amgen Inc. with small molecules from the plate of the former Onyx Pharmaceuticals Inc., the South San Francisco company is developing drugs for autoimmune diseases, where the immune system starts attacking healthy cells. Its first drug, KZR-616, is enrolling patients in a mid-stage Phase Ib/II study in lupus and lupus nephritis, or inflammation in the kidney.

  • What Drove Ionis’s Revenue in Q1
    Market Realist15 hours ago

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.

  • Ionis Pharmaceuticals’ Valuation on May 23
    Market Realist17 hours ago

    Ionis Pharmaceuticals’ Valuation on May 23

    Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.

  • Analyst Views on the Upside Potential of Alnylam Pharmaceuticals
    Market Realist17 hours ago

    Analyst Views on the Upside Potential of Alnylam Pharmaceuticals

    How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals (ALNY) is a global biopharmaceutical company focused on developing RNA interference-based novel therapeutics. Alnylam is harnessing this pathway to develop a new class of innovative medicines called RNAi therapeutics.

  • ETF Trends22 hours ago

    Will “Right to Try” Bill Boost Biotech ETFs?

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, and other biotechnology assets traded slightly higher Wednesday after the U.S. House of Representatives on Tuesday passed “right to try” legislation. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.

  • InvestorPlace23 hours ago

    3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More

    A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.

  • Is This Little Biotech the Best Migraine Stock to Buy Now?
    Motley Foolyesterday

    Is This Little Biotech the Best Migraine Stock to Buy Now?

    The big dogs have a head start, but this small-cap biotech could have a lot more to gain.

  • Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
    Zacks2 days ago

    Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx

    Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.

  • Forbes2 days ago

    New Drug Costs Are Still High, But Putting Prices In TV Ads Offers Little Value

    Last week, the Trump administration, via secretary of health and human services, Alex Azar, proposed that drug makers be required to include the list prices of drugs in all direct-to-consumer ads. In addition, payers are providing support for the prices being set. Just last week, Amgen announced that the price of its new migraine drug, Aimovig, would be set at $6,900 per year.

  • Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene
    Investor's Business Daily3 days ago

    Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene

    Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.

  • Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
    Market Realist3 days ago

    Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.

  • Amgen's Label Expansion Application for Prolia Gets FDA Nod
    Zacks3 days ago

    Amgen's Label Expansion Application for Prolia Gets FDA Nod

    Amgen (AMGN) announces FDA approval for its regulatory application seeking label expansion for Prolia.

  • Benzinga3 days ago

    Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 21) AstraZeneca plc (ADR) (NYSE: AZN ) (FDA approved its ...

  • The Wall Street Journal3 days ago

    New Migraine Drugs Offer Hope to Sufferers

    Lisa DeLeonardo set a Google alert so she would know exactly when the first in a new class of migraine drugs was approved. It happened Thursday, when the U.S. Food and Drug Administration approved Amgen and Novartis’ application for erenumab, whose brand name is Aimovig. It’s an injectable drug touted as the first treatment designed specifically to prevent migraines, and is expected to be available to patients within a week for an annual price of $6,900.

  • Regional cycling fans show up in numbers for Amgen Tour (PHOTOS)
    American City Business Journals4 days ago

    Regional cycling fans show up in numbers for Amgen Tour (PHOTOS)

    Northern California showed itself to be an accommodating and receptive host for the 13th annual Amgen Tour of California.

  • Company News For May 21, 2018
    Zacks4 days ago

    Company News For May 21, 2018

    Companies in the news are: PYPL,AMGN,TTD,CBS

  • Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod
    Zacks4 days ago

    Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod

    Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.

  • TheStreet.com7 days ago

    CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

    After a heated week of litigation battles, CBS on Thursday proceeded with a board meeting it had scheduled to vote on whether to dilute the voting power of National Amusements Inc., a company controlled by Shari Redstone. This came after a court decision that said CBS could not prevent Redstone from changing CBS's bylaws to prevent that from occurring. All of which means CBS directors and Redstone will be back in court soon to fight over voting control, with Redstone pushing to combine CBS with Viacom, unless of course, both sides instead consider the option to auction the media company.

  • CNBC7 days ago

    Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

    One Wall Street analyst predicts the anti-migraine category could be a $1 billion to $2 billion business over the next five years. Michael Yee, managing director at Jefferies, expects others companies to get into the migraine treatment sector. The anti-migraine drug Aimovig from Amgen AMGN and Novartis NVS could become a $1 billion to $2 billion business over the next five years, said a Wall Street analyst.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks7 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Investopedia7 days ago

    10 Stocks That Will Thrive On Buybacks

    Buyback Boost: Repurchases are more likely to bolster these stocks

  • Moody's7 days ago

    Novartis AG -- Moody's: Aimovig approval credit positive for Amgen and Novartis

    Moody's Investors Service commented that the recent US Food and Drug Administration (FDA) approval of Aimovig for chronic migraines is credit positive for the Amgen Inc. (Baa1 stable) and Novartis AG (Aa3 negative). For additional information, please see Moody's Issuer Comment available on www.moodys.com. This publication does not announce a credit rating action.

  • Amgen's migraine treatment focuses on huge un-met need, s...
    CNBC Videos7 days ago

    Amgen's migraine treatment focuses on huge un-met need, s...

    Michael Yee, Jefferies, discusses what Amgen’s new migraine treatment means for the company and the pharma space.

  • FDA approves new migraine-prevention drug
    CNBC Videos7 days ago

    FDA approves new migraine-prevention drug

    CNBC's Meg Tirrell reports on the newest class of migraine drugs called Aimovig, aproved by the FDA to treat powerful headaches.